Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
NeyroblastGX LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, creating separate examination tracks for the active portfolio.
KASAYAN, KATRIEL BARCELLANO is the busiest listed examiner, with 1 pending matter. Counsel should coordinate overall claim strategy while tailoring the substantive response to each examiner’s treatment of the therapeutic technology.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324091 | FULLY FUNCTIONAL CONTRACTILE GASTROINTESTINAL ORGANOID SYSTEM, GENERATED FROM HUMAN-INDUCED PLURIPOTENT STEM CELLS TO DEVELOP A HIGH THROUGHPUT SYSTEM FOR DETECTING EXISTING AND NEWLY-EMERGING PATHOGENS, DRUGS, TOXICITY AND THEREOF | KASAYAN, KATRIEL BARCELLANO | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324105 | GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS | HOLTZMAN, KATHERINE ANN | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324105 | GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS | HOLTZMAN, KATHERINE ANN | 1646 | §103 | Final Rejection | 49d overdue | Pending | May 25, 2023 |
| 18324091 | FULLY FUNCTIONAL CONTRACTILE GASTROINTESTINAL ORGANOID SYSTEM, GENERATED FROM HUMAN-INDUCED PLURIPOTENT STEM CELLS TO DEVELOP A HIGH THROUGHPUT SYSTEM FOR DETECTING EXISTING AND NEWLY-EMERGING PATHOGENS, DRUGS, TOXICITY AND THEREOF | KASAYAN, KATRIEL BARCELLANO | 1634 | §103 | Final Rejection | 8d overdue | Pending | May 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeyroblastGX LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Katherine Ann Holtzman has the most, with 1 of NeyroblastGX LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
